Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? (Q38931441)

7 September 2017

1 reference

title

Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? (English)

1 reference

7 September 2017

1 reference

1 reference

Linde Meyaard

4

0 references

author name string

Michiel van der Vlist

series ordinal

1

1 reference

7 September 2017

Jurgen Kuball

series ordinal

2

1 reference

7 September 2017

Timothy R D Radstake

series ordinal

3

1 reference

7 September 2017

language of work or name

English

0 references

publication date

19 August 2016

1 reference

Nature Reviews Rheumatology

7 September 2017

published in

1 reference

7 September 2017

volume

12

1 reference

7 September 2017

issue

10

1 reference

7 September 2017

page(s)

593-604

1 reference

Disease tolerance as a defense strategy

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Immune inhibitory receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Immunoreceptor tyrosine-based inhibition motifs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Do inhibitory immune receptors play a role in the etiology of autoimmune disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Breakthrough of the year 2013. Cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

The future of immune checkpoint therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

The role of CTLA-4 in the regulation and initiation of T-cell responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Molecular and cellular insights into T cell exhaustion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

The Basis of Oncoimmunology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Ipilimumab in patients with cancer and the management of dermatologic adverse events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

CANCER IMMUNOLOGY. The "cancer immunogram".

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Organizing pneumonia as a side effect of ipilimumab treatment of melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor Treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

31 March 2020

SeXX matters in immunity

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Systemic lupus erythematosus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

CD200 receptor controls sex-specific TLR7 responses to viral infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Ipilimumab in patients with melanoma and autoimmune disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

The soluble leukocyte-associated Ig-like receptor (LAIR)-2 antagonizes the collagen/LAIR-1 inhibitory immune interaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

PECAM-1: old friend, new partners

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Immune checkpoint receptors in regulating immune reactivity in rheumatic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic scl

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

An update on an immune system that goes awry in systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

The IL-23-IL-17 axis in inflammatory arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Cutting edge: TIGIT has T cell-intrinsic inhibitory functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

TIGIT overexpression diminishes the function of CD4 T cells and ameliorates the severity of rheumatoid arthritis in mouse models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Vstm3 is a member of the CD28 family and an important modulator of T-cell function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Acceleration of the onset of collagen‐induced arthritis by a deficiency of platelet endothelial cell adhesion molecule 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

The Inhibitory Co-Receptor, PECAM-1 Provides a Protective Effect in Suppression of Collagen-Induced Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

TCR stimulation drives cleavage and shedding of the ITIM receptor CD31.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Upholding the T cell immune-regulatory function of CD31 inhibits the formation of T/B immunological synapses in vitro and attenuates the development of experimental autoimmune arthritis in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Systemic increase in type I interferon activity in Sjögren's syndrome: a putative role for plasmacytoid dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Neutrophil extracellular traps kill bacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

PILRalpha, a novel immunoreceptor tyrosine-based inhibitory motif-bearing protein, recruits SHP-1 upon tyrosine phosphorylation and is paired with the truncated counterpart PILRbeta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Signal inhibitory receptor on leukocytes-1 is a novel functional inhibitory immune receptor expressed on human phagocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Ligation of signal inhibitory receptor on leukocytes-1 suppresses the release of neutrophil extracellular traps in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Neutrophil infiltration during inflammation is regulated by PILRα via modulation of integrin activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

PILRα negatively regulates mouse inflammatory arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Characterization of the CD200 receptor family in mice and humans and their interactions with CD200.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

CD200R signaling in tumor tolerance and inflammation: A tricky balance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Immune inhibitory ligand CD200 induction by TLRs and NLRs limits macrophage activation to protect the host from meningococcal septicemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

CD200R1 regulates the severity of arthritis but has minimal impact on the adaptive immune response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

CD200R/CD200 inhibits osteoclastogenesis: new mechanism of osteoclast control by mesenchymal stem cells in human

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

A role for the immunomodulatory molecules CD200 and CD200R in regulating bone formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Aberrant CD200/CD200R1 expression and its potential role in Th17 cell differentiation, chemotaxis and osteoclastogenesis in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Immunoglobulin isotype knowledge and application to Fc engineering

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Treatment of murine lupus with CTLA4Ig

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Switched at birth: a new family for PECAM-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

FDF03, a novel inhibitory receptor of the immunoglobulin superfamily, is expressed by human dendritic and myeloid cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.131

Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27539666

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Blockade of Fc receptor-mediated binding to U-937 cells by murine monoclonal antibodies directed against a variety of surface antigens

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27539666

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRRHEUM.2016.131

1 reference

Dimensions Publication ID

7 September 2017

1039491123

0 references

1 reference